Deal Tracker · Countries

India pharma licensing deals

11 licensing deals involving India tracked by EPT (2024–2026). Most active: Biocon, ADCAN Pharma, Dr. Reddy's Laboratories & Ajanta Pharma. Latest: Gilead Sciences → Dr. Reddy's Laboratories (Licensing, 16 Nov 2026).

11
deals tracked
8
announced in 2026
$80m
disclosed value (1 deal)
100%
licensing, the top deal type
  • EPT has tracked 11 India pharma licensing deals (2024–2026), 8 of them announced in 2026.
  • The countries that appear most often are Saudi Arabia (4), UAE (2), Brazil (1) & Chile (1).
  • Values were disclosed for 1 of 11 deals, totalling $80m; the largest is Orchid Pharma → Laboratorio Libra ($80m, 24 Oct 2026).
  • The most active companies: Biocon (3), ADCAN Pharma (2) & Dr. Reddy's Laboratories (2).

Most active companies

Biocon (3) · ADCAN Pharma (2) · Dr. Reddy's Laboratories (2)

Countries involved

Saudi Arabia (4) · UAE (2) · Brazil (1) · Chile (1) · China (1) · Indonesia (1)

Largest disclosed deals

Questions

How many India pharma licensing deals has EPT tracked?
11 as of 16 Nov 2026, covering 2024–2026; 8 were announced in 2026. The most recent is Gilead Sciences → Dr. Reddy's Laboratories (Licensing, 16 Nov 2026).
Which companies are most active in India pharma licensing deals?
Biocon (3 deals), ADCAN Pharma (2 deals), Dr. Reddy's Laboratories (2 deals).
What is the largest disclosed India pharma licensing deal?
Orchid Pharma → Laboratorio Libra: $80m (Licensing, 24 Oct 2026). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)